Jonathan Miller
Stock Analyst at Evercore ISI
(0.42)
# 4,046
Out of 4,382 analysts
52
Total ratings
27.1%
Success rate
-7.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintained: Buy | $15 | $2.71 | +453.51% | 3 | May 27, 2026 | |
| NKTX Nkarta | Maintained: Buy | $9 | $2.51 | +258.57% | 1 | May 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $74 → $76 | $51.84 | +46.60% | 2 | May 11, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $23 → $22 | $13.35 | +64.79% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Maintained: Buy | $25 | $6.37 | +292.46% | 2 | May 5, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $14 → $16 | $13.54 | +18.17% | 5 | Apr 28, 2026 | |
| ERAS Erasca | Maintained: Buy | $11 → $24 | $11.97 | +100.50% | 2 | Apr 28, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $18 → $4 | $1.12 | +257.14% | 2 | Apr 13, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintained: Buy | $45 → $23 | $8.64 | +166.20% | 4 | Apr 13, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $13 → $15 | $6.63 | +126.24% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $24.04 | +99.67% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 → $13 | $1.92 | +577.08% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.19 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $19 | $7.42 | +156.06% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.18 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.25 | +41.18% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $11.26 | +6.57% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $4.58 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.92 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.80 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.92 | n/a | 2 | May 5, 2021 |
Editas Medicine
May 27, 2026
Maintained: Buy
Price Target: $15
Current: $2.71
Upside: +453.51%
Nkarta
May 18, 2026
Maintained: Buy
Price Target: $9
Current: $2.51
Upside: +258.57%
CRISPR Therapeutics AG
May 11, 2026
Maintained: Buy
Price Target: $74 → $76
Current: $51.84
Upside: +46.60%
Janux Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $23 → $22
Current: $13.35
Upside: +64.79%
Entrada Therapeutics
May 5, 2026
Maintained: Buy
Price Target: $25
Current: $6.37
Upside: +292.46%
Intellia Therapeutics
Apr 28, 2026
Maintained: Hold
Price Target: $14 → $16
Current: $13.54
Upside: +18.17%
Erasca
Apr 28, 2026
Maintained: Buy
Price Target: $11 → $24
Current: $11.97
Upside: +100.50%
PMV Pharmaceuticals
Apr 13, 2026
Maintained: Buy
Price Target: $18 → $4
Current: $1.12
Upside: +257.14%
4D Molecular Therapeutics
Apr 13, 2026
Maintained: Buy
Price Target: $45 → $23
Current: $8.64
Upside: +166.20%
Aura Biosciences
Apr 13, 2026
Maintained: Buy
Price Target: $13 → $15
Current: $6.63
Upside: +126.24%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $24.04
Upside: +99.67%
Mar 9, 2026
Maintained: Buy
Price Target: $1 → $13
Current: $1.92
Upside: +577.08%
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $23.19
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: $110 → $19
Current: $7.42
Upside: +156.06%
Jan 26, 2026
Maintained: Buy
Price Target: n/a
Current: $4.18
Upside: -
Nov 28, 2025
Maintained: Buy
Price Target: $6
Current: $4.25
Upside: +41.18%
Sep 30, 2025
Maintained: Buy
Price Target: $12
Current: $11.26
Upside: +6.57%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $4.58
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: n/a
Current: $3.92
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.80
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $9.92
Upside: n/a